The first pill version of the blockbuster GLP-1 weight loss drugs has been launched in the US by Novo Nordisk at a lower cost than jab varieties, accelerating a price war in the sector
This article is exclusive to STAT+ subscribers Unlock this article plus daily market-moving biopharma analysis by subscribing to STAT+
Gastrointestinal side effects were the most commonly reported adverse events, were generally mild to moderate in severity, and usually occurred during the dose escalation period
Squid glutathione S-transferase
The day after the announcement, the top lawyer for the Department of Health and Human Services, Mike Stuart, announced on X that his office had referred Hims & Hers to the Justice Department for potential violations of the Federal Food, Drug and Cosmetic Act, which regulates the sale of medications
Fresher products provide longer useful life